Literature DB >> 15139487

Nizatidine and cisapride increase salivary secretion in rats.

Kyoichi Adachi1, Kenji Furuta, Tomoko Katsube, Tomoo Fujisawa, Takane Azumi, Hirofumi Fujishiro, Shunji Ishihara, Yuji Amano, Yoshikazu Kinoshita.   

Abstract

Saliva is a neurally induced solution with buffering capacity against acidic solutions. Salivation therefore plays an important role in defending the esophageal mucosa against refluxed gastric acid and is evoked by cholinergic stimulation. Both nizatidine and cisapride are reported to increase acetylcholine concentrations in the postganglionic cholinergic synapses. We performed this study to clarify the effect of administration of nizatidine and cisapride on salivary secretion. Eight-week-old male Sprague-Dawley rats were used for the experiments. Histamine-stimulated gastric acid secretion was measured after intraduodenal administration of nizatidine or famotidine to determine the equipotent acid-suppressing doses. Salivary secretion was then measured for 3 hr after intraduodenal administration of nizatidine (30 mg/kg), famotidine (3 mg/kg), or cisapride (1 mg/kg). Both nizatidine and famotidine dose-dependently inhibited histamine-stimulated gastric acid secretion. Total salivary secretion was significantly increased by nizatidine (P = 0.02) and cisapride (P = 0.02) but not by famotidine (P = 0.50) compared with controls.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15139487     DOI: 10.1023/b:ddas.0000020492.16088.28

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat.

Authors:  S Ueki; Y Matsunaga; T Yoneta; H Tamaki; Z Itoh
Journal:  Arzneimittelforschung       Date:  1999-07

2.  Effect of esophageal emptying and saliva on clearance of acid from the esophagus.

Authors:  J F Helm; W J Dodds; L R Pelc; D W Palmer; W J Hogan; B C Teeter
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

Review 3.  Pathogenesis of reflux esophagitis.

Authors:  W J Dodds; W J Hogan; J F Helm; J Dent
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

4.  Parotid salivary flow and composition during infusion of acetylcholine and atropine into the carotid artery of conscious sodium-replete sheep.

Authors:  A M Beal
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1979-04

5.  Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations.

Authors:  C M Bate; P W Keeling; C O'Morain; S P Wilkinson; D N Foster; R A Mountford; J M Temperley; R F Harvey; D G Thompson; M Davis
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

6.  R 50 595, a selective non-competitive antagonist of cisapride, BRL 24924 and 5-hydroxytryptamine on the guinea-pig ileum.

Authors:  H W Van den Brink; J A Schuurkes; J M Van Nueten; J M Van Rossum
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

7.  Nizatidine and cisapride enhance salivary secretion in humans.

Authors:  K Adachi; M Ono; A Kawamura; M Yuki; H Fujishiro; Y Kinoshita
Journal:  Aliment Pharmacol Ther       Date:  2002-02       Impact factor: 8.171

8.  Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.

Authors:  G F Goldin; M Marcinkiewicz; T Zbroch; L P Bityutskiy; R W McCallum; J Sarosiek
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

9.  Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats.

Authors:  S Ueki; M Seiki; T Yoneta; H Aita; K Chaki; Y Hori; H Morita; E Tagashira; Z Itoh
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

10.  A comparison of five maintenance therapies for reflux esophagitis.

Authors:  S Vigneri; R Termini; G Leandro; S Badalamenti; M Pantalena; V Savarino; F Di Mario; G Battaglia; G S Mela; A Pilotto
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  1 in total

1.  Glutaraldehyde-crosslinked chitosan-polyethylene oxide nanofibers as a potential gastroretentive delivery system of nizatidine for augmented gastroprotective activity.

Authors:  Walaa Ebrahim Abd El Hady; Osama Abd El-Aazeem Soliman; Hassan Mohamed El Sabbagh; Elham Abdelmonem Mohamed
Journal:  Drug Deliv       Date:  2021-08-24       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.